Capricor Therapeutics, Inc. 2023 Q3 Form 10-Q Summary
Business Context and Reporting Period
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies, primarily CAP-1002 for Duchenne muscular dystrophy (DMD), and a preclinical engineered exosome platform. The unaudited report covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods. The company has no approved products and has not generated commercial product sales.
Financial Performance and Position
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $6.2 million | $1.6 million | $13.1 million | $1.6 million |
| Research and development expense | $10.0 million | $5.5 million | $26.5 million | $15.6 million |
| General and administrative expense | $3.0 million | $2.6 million | $9.4 million | $7.6 million |
| Net loss | $6.4 million | $6.4 million | $21.5 million | $21.3 million |
| Loss per share | $0.25 | $0.26 | $0.85 | $0.87 |
| Operating cash flow | Not separately provided | Not separately provided | $(14.0) million | $11.8 million |
Revenue primarily reflects recognition of the $30.0 million upfront payment under the U.S. Nippon Shinyaku distribution agreement as Capricor conducts the HOPE-3 trial. The company recognized approximately $6.2 million in Q3 and $13.1 million in the first nine months of 2023. The $12.0 million upfront payment under the Japan distribution agreement remained deferred revenue because the company had not identified a distinct performance obligation.
As of September 30, 2023, cash and cash equivalents were $9.0 million and marketable securities were $19.5 million, for total cash, cash equivalents and marketable securities of approximately $28.5 million, down from $41.4 million at December 31, 2022. Working capital was negative $3.4 million and stockholders’ equity was negative $1.8 million. Total liabilities were $38.9 million, including $26.4 million of deferred revenue. The filing does not report conventional funded debt; liabilities primarily consist of deferred revenue, lease liabilities and the CIRM liability.
Cash used in operating activities was $14.0 million. Investing activities provided $11.0 million, primarily from net sales and maturities of marketable securities, while financing activities provided $2.4 million, principally from equity sales and stock award exercises. Stock-based compensation was $5.5 million for the first nine months.
Material Changes Versus the Prior Comparable Period
- Q3 revenue increased by approximately 289% and nine-month revenue increased by approximately 722%, driven by recognition of the U.S. distribution agreement upfront payment.
- Q3 R&D expense increased 82% to $10.0 million; nine-month R&D expense increased 70% to $26.5 million. The principal driver was higher CAP-1002 spending related to HOPE-3, the HOPE-2 open-label extension study and manufacturing scale-up.
- Q3 G&A expense increased 18% and nine-month G&A expense increased 23%, primarily due to higher stock-based compensation, personnel and facility expenses.
- Nine-month operating cash flow shifted from $11.8 million provided in 2022 to $14.0 million used in 2023, reflecting the prior-period benefit of the U.S. upfront payment and increased operating expenditures.
- Marketable securities declined by $12.3 million from year-end 2022, while deferred revenue increased on a current basis as the Japan upfront payment was recorded.
- Shares outstanding increased from 25.2 million at December 31, 2022 to 25.9 million at September 30, 2023, excluding subsequent financing activity.
Guidance, Outlook, Risks and Unusual Items
- Management estimated that cash, cash equivalents and marketable securities, including the subsequent financing, would fund operating expenses and capital expenditures into 2025. The filing also states that available resources are sufficient for at least the next twelve months, but the company expects substantial additional capital needs.
- On October 3, 2023, after quarter-end, Capricor completed a registered direct offering of 4,935,621 shares at $4.66 per share for gross proceeds of approximately $23.0 million. Each share included a warrant to purchase one share at $5.70; the warrants are exercisable six months after issuance and expire seven years after issuance. The financing will materially increase shares outstanding and potential dilution.
- HOPE-3 Cohort A reached target enrollment of 58 patients. Management expected to report the interim futility analysis in the fourth quarter of 2023 and top-line Cohort A data in the fourth quarter of 2024. Cohort B, expected to enroll approximately 44 patients, was planned to begin enrollment in the fourth quarter of 2023 to support inclusion of the San Diego GMP manufacturing site.
- Management planned to request an FDA meeting in the first quarter of 2024 regarding chemistry, manufacturing and controls and potential expedited approval pathways. A potential BLA would be supported by Cohort A results and the Los Angeles manufacturing site.
- Management expected 2023 CAP-1002 program spending of approximately $20.0 million to $24.0 million and exosome-program spending of approximately $2.5 million to $3.5 million.
- The company remains dependent on successful clinical development, regulatory approval, manufacturing scale-up, additional financing and potential collaboration or licensing arrangements. Failure to obtain funding could delay, curtail or terminate clinical and research programs and could dilute existing shareholders.
- The CIRM award is recorded as a $3.4 million liability because Capricor may elect to convert it into a loan. If converted, repayment and interest obligations could arise; the award also includes potential revenue-sharing requirements.
- No material legal proceedings were pending, and management reported no material changes to previously disclosed risk factors.
Most Important Facts for Investors to Verify
- Progress, interim analysis results and eventual top-line data from the HOPE-3 Phase 3 trial.
- FDA feedback, BLA timing, expedited pathway eligibility and the regulatory acceptability of the Los Angeles and San Diego manufacturing sites.
- Actual cash runway after the October 2023 financing, ongoing cash burn and the timing or need for additional capital.
- The effect of the October financing warrants and shares on dilution, ownership and future equity needs.
- Revenue recognition assumptions for the Nippon Shinyaku agreements, including the timing of the remaining approximately $14.4 million of U.S. agreement performance obligations.
- Whether potential development, regulatory and sales milestones under the U.S. and Japan agreements are achieved; these amounts remain contingent and are not included in recognized revenue.
- Clinical-trial accrual estimates, manufacturing costs, licensing obligations, CIRM repayment or revenue-sharing exposure and the commercial viability of CAP-1002.